Loading…
Reported covered position: Legislative Assistant, Rep. Zoe Lofgren
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to H.R. 1, The Tax Cuts & Jobs Act, including the Orphan Drug Tax Credit, corporate tax rate, foreign earnings rate, and employee benefits.
OPEN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Source: Senate LDA
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 1223 - OPEN Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act to authorize extension of exclusivity periods for certain drugs approved for a new indication for a rare disease or condition.
American Health Care Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430 - FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
American Health Care Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430, the FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
American Health Care Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 1223 - OPEN Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act to authorize extension of exclusivity periods for certain drugs approved for a new indication for a rare disease or condition.
FDA Reauthorization Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430 - FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
FDA Reauthorization Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430, the FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
HEALTHY KIDS Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
HEALTHY KIDS Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
KIDS Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
KIDS Act of 2017
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Precision Medicine Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Advancing Precision Medicine Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Precision Medicine Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Advancing Precision Medicine Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
A resolution designating the month of May 2016 as "Cystic Fibrosis Awareness Month".
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
21st Century Cures Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Innovation Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 9 Innovation Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Ensuring Access to Clinical Trials Act of 2015
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Advancing Targeted Therapies for Rare Diseases Act of 2016
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Drug Quality and Security Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Patent Transparency and Improvements Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Drug Quality and Security Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Drug Quality and Security Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Patients' Access to Treatments Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Part D Beneficiary Appeals Fairness Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Patent Transparency and Improvements Act of 2013
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · first_quarter · 1A
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · first_quarter · Q1
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to H.R. 1, The Tax Cuts & Jobs Act, including the Orphan Drug Tax Credit, corporate tax rate, foreign earnings rate, and employee benefits.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430 - FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · second_quarter · Q2
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430, the FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 1223 - OPEN Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act to authorize extension of exclusivity periods for certain drugs approved for a new indication for a rare disease or condition.
Issues related to rare disease and orphan disease patient access in Medicaid.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · third_quarter · Q3
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · first_quarter · Q1
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · fourth_quarter · Q4
H.R. 9 Innovation Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · third_quarter · Q3
H.R. 9 Innovation Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · second_quarter · Q2
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · first_quarter · Q1
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · fourth_quarter · Q4
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · third_quarter · Q3
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Issues related to Camp Comprehensive Tax Reform draft (no specific bills)
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · second_quarter · Q2
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Issues related to Camp Comprehensive Tax Reform draft (no specific bills); Issues related to the Orphan Drug Tax Credit (no specific bills)
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · fourth_quarter · Q4
Issues related to the Orphan Drug Tax Credit (no specific bills)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · third_quarter · Q3
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to comprehensive corporate tax reform (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 9 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 9 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE